RxDoctor Payments Data

Taslima Bhuiyan, MD

Cardiovascular Disease · Lilburn, GANPI 1588824346

Payments from drug & device makers

$2,847in general payments, 2019–2025

Across 156 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$379
  • Johnson & Johnson$285
  • Boehringer Ingelheim$234
  • W. L. Gore & Associates, Inc.$230
  • Novo Nordisk$207
  • Merck$192
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,847 in reported general payments places this provider in the 50th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$202,000
Medicare patients
1,364
Services billed
4,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban536$680,440
JardianceEmpagliflozin346$435,945
EntrestoSacubitril/Valsartan63$82,188
Repatha SureclickEvolocumab74$78,862
XareltoRivaroxaban62$66,441
FarxigaDapagliflozin Propanediol44$60,608
Repatha PushtronexEvolocumab44$48,511
Praluent PenAlirocumab31$20,489
Metoprolol Succinate757$9,530
Atorvastatin Calcium667$6,330
Ranolazine ErRanolazine37$4,871
Valsartan193$3,486
Isosorbide Mononitrate ErIsosorbide Mononitrate246$3,350
Rosuvastatin Calcium257$3,148
Midodrine Hcl18$2,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$680,440536 claims
Boehringer IngelheimJardiance$234$435,945346 claims
NovartisEntresto$379$82,18863 claims
Johnson & JohnsonXarelto$285$66,44162 claims
AstraZenecaFarxiga$160$60,60844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Lilburn

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →